Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer

Figure 5

Intravesical PstS1 treatment after sensitization with PBS, PLG-particles or PLG-particles/BSA. Ten days before inoculation of MB-49 tumor cells mice were s.c. sensitized by injection of PBS (A), L-particles (B) or L-particles loaded with BSA (C). On days 1, 8, 15 and 22 after tumor challenge, mice were treated by intravesical instillation of PstS1 (A/B/C). Mice which received s.c. PBS and intravesical PBS served as control. Survival of mice was analyzed by Kaplan-Meier curve and log rank test.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us